Vaccine for preventing and treating porcine progressive atrophic rhinitis

Abstract

The present invention relates to an animal vaccine directed to progressive atrophic rhinitis (PAR), comprising at least two fragmens of recombinant subunit Pasteurella multocida toxins (rsPMT) capable of eliciting the production of antibodies against Pasteurella multocida associated with PAR, said fragments each having an amino acid sequence that substantially corresponds to the 2-486, 486-986 or 986-1281 amino acid residues of Pasteurella multocida toxin (PMT), respectively. Also disclosed is a multivalent animal vaccine, comprising said fragments as active components against PAR, and at least a pathogenic antigen or epitope thereof associated with other animal disease(s), such as inactivated gE-deleted Pseudorabies virus.

1 . A vaccine for immunizing animal against progressive atrophic rhinitis (PAR), which comprising a combination of at least two fragments of recombinant subunit  Pasteurella multocida  toxins (rsPMT) each having an amino acid sequence that substantially corresponds to the 2-486, 486-986 or 986-1281 amino acid residues in SEQ ID No: 2.  
     
     
         2 . The vaccine of  claim 1 , wherein the fragments having an amino acid sequence that substantially corresponds to the 2-486 and 986-1281 amino acid residues of  Pasteurella multocida  toxin (PMT) respectively.  
     
     
         3 . The vaccine of  claim 1 , wherein the fragments having an amino acid sequence that substantially corresponds to the 2-486, 486-986 and 986-1281 amino acid residues of  Pasteurella multocida  toxin (PMT) respectively.  
     
     
         4 . The vaccine of  claim 3 , wherein the fragments of PMT are derived from the recombinant subunit  Pasteurella multocida  toxins (rsPMT) of serotype D isolate.  
     
     
         5 . The vaccine of  claim 1 , wherein the fragment of rsPMT is produced by recombinant DNA technology.  
     
     
         6 . The vaccine of  claim 5 , wherein the fragment of rsPMT is expressed in  E. coli  transformant with a plasmid comprising the coding sequence of  Pasteurella multocida  toxin fragment 2-486, 486-986 and/or 986-1281.  
     
     
         7 . The vaccine of  claim 1 , which further comprising at least one antigen derived from PMT toxoid, serotype A  Pasteurella multocida , serotype D  Pasteurella multocida  or  Bordetella bronchiseptica.    
     
     
         8 . The vaccine of  claim 1 , which further comprising at least one adjuvant selected from Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum gel, oily adjuvant (W/O/W), water-in-oil (W/O) emulsion, oil-in-water (W/O) emulsion, Con A, β-glucosan, and combination thereof.  
     
     
         9 . A multivalent vaccine against progressive atrophic rhinitis (PAR), which comprising a combination of at least two fragments of PMT described in  claim 1  as the first component; and at least one antigen or epitope associated with another animal pathology.  
     
     
         10 . The multivalent vaccine of  claim 9 , which comprising inactivated gE-deleted Pseudorabies virus as the second component.  
     
     
         11 . The multivalent vaccine of  claim 9 , which further comprising at least one antigen derived from PMT toxoid,  Pasteurella multocida  serotype A,  Pasteurella multocida  serotype D or  Bordetella bronchiseptica.    
     
     
         12 . The multivalent vaccine of  claim 9 , which further comprising at least one adjuvant selected from Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum gel, oily adjuvant (W/O/W) water-in-oil (W/O) emulsion, oil-in-water (O/W) emulsion, Con A, β-glucosan, and combination thereof.  
     
     
         13 . The multivalent vaccine of  claim 9 , wherein the fragments of PMT are derived from the recombinant subunit  Pasteurella multocida  toxins (rsPMT) of serotype D isolate.  
     
     
         14 . The multivalent vaccine of  claim 9 , wherein the fragments of PMT and the PR are produced by recombinant DNA technology.